No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 – 50
Sex
Any
Study type
Interventional
Purpose
Prevention
Participants needed
60 (estimated)
Sponsor
University of Illinois at Chicago · Other
Who this trial is looking for
This trial is looking for individuals with obesity and diabetes to understand how certain fat cells affect blood vessel health. Participation involves being part of a study that examines these fat cells and their impact on your condition.
Are You a Good Fit for This Trial?
You may be able to join if
I am 18 to 50 years old.
I have a BMI of 35 or higher.
I have been diagnosed with diabetes.
I am not pregnant.
I have medical clearance to exercise.
You may not be able to join if
I am pregnant.
I currently smoke.
I abuse alcohol or drugs.
I have chronic heart, liver, or kidney diseases.
I have autoimmune diseases.
I have cancer.
I do not speak English.
I have had allergic reactions to lidocaine.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
The development of type II diabetes (T2D) is strongly associated with obesity and both are well-established risk factors for cardiovascular disease. Knowing that vascular dysfunction is an early event in the development of cardiovascular disease in obese diabetic (OB-T2D) patients, The investigators set their long-term goal to define molecular mechanisms of vascular dysfunction and corrective stra…
The development of type II diabetes (T2D) is strongly associated with obesity and both are well-established risk factors for cardiovascular disease. Knowing that vascular dysfunction is an early event in the development of cardiovascular disease in obese diabetic (OB-T2D) patients, The investigators set their long-term goal to define molecular mechanisms of vascular dysfunction and corrective strategies that target these mechanisms such as physical activity and weight loss. The investigators recently discovered that human adipose tissues release extracellular vesicles (adiposomes) that are efficiently captured by endothelial cells. Adiposomes are known to carry bioactive cargos such as proteins and micro RNAs; however, their lipid content has not been studied nor has their ability to transfer their lipid cargo to endothelial cells. In the current application, the investigators propose to investigate the role of adiposomes in communicating the unhealthy milieu, mainly dysregulated lipids, to endothelial cells in OB-T2D subjects. On top of these lipid species that the investigators propose to be carried by adiposomes are glycosphingolipids (GSLs). These lipids originate from the glycosylation of ceramides, a chemical process that is upregulated in the presence of inflammation and high glucose levels. Preliminary findings showed that in endothelial cells, GSL-rich adiposomes disturb plasma membrane structure and subsequently induce endothelial dysfunction. Moreover, the investigators found that preconditioning endothelial cells with high shear stress (which is an exercise mimetic) protected endothelial cells from the detrimental effects induced by adiposomes. Therefore, the central hypothesis is that adipose tissues in OB-T2D patients release GSL-loaded adiposomes that induce vascular endothelial dysfunction. The researchers propose that exercise and weight loss interventions (bariatric surgery) will restore adipose tissue homeostasis, reduce GSL-loaded adiposomes, and subsequently alleviate vascular risk in OB-T2D patients. The investigators will test the hypotheses by pursuing the following aims: aim 1: Investigate the role of GSL-rich adiposomes in the pathogenesis of endothelial dysfunction in OB-T2D adults; aim 2: Test the effectiveness of exercise training in reducing adiposome-mediated effects on vascular function; and aim 3: Examine changes in adiposome/caveolae axis following metabolic surgery and their association with vascular function.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* BMI ≥ 35 kg/m2
* Between ages 18-50 years
* Not pregnant
* Diabetic (Current use of diabetes medication or fasting glucose ≥126 mg/dL)
* Medical clearance to participate in a moderate-intensity exercise program
Exclusion Criteria:
* Pregnant women
* Current smokers
* Current…
Inclusion Criteria:
* BMI ≥ 35 kg/m2
* Between ages 18-50 years
* Not pregnant
* Diabetic (Current use of diabetes medication or fasting glucose ≥126 mg/dL)
* Medical clearance to participate in a moderate-intensity exercise program
Exclusion Criteria:
* Pregnant women
* Current smokers
* Currently abusing alcohol or drugs
* Chronic heart, liver, or kidney diseases, autoimmune diseases, or cancer
* Non-English speakers
* History of allergic reactions to lidocaine
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.